Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas

OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143

(2017) D. A. Reardon et al.   NEURO-ONCOLOGY

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency

(2016) Eric Bouffet et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

(2016) Sarah B Goldberg et al.   LANCET ONCOLOGY

Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti–PD-1 treatment with nivolumab

(2016) Patrick Roth et al.   NEURO-ONCOLOGY

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies

(2016) Sarah T. Garber et al.   NEURO-ONCOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study

(2015) Marc C. Chamberlain   JOURNAL OF NEURO-ONCOLOGY

PD-L1 expression and prognostic impact in glioblastoma

(2015) Edjah K. Nduom et al.   NEURO-ONCOLOGY

Immunotherapeutic Advancements for Glioblastoma

(2015) Leonel Ampie et al.   Frontiers in Oncology

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

(2014) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

(2012) Roger Stupp et al.   EUROPEAN JOURNAL OF CANCER

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE